INT339094

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2010
Last Reported 2010
Negated 0
Speculated 4
Reported most in Body
Documents 1
Total Number 68
Disease Relevance 67.79
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

methyltransferase activity (Ezh2) chromosome (Ezh2) nucleus (Ezh2)
DNA binding (Ezh2)
Anatomy Link Frequency
lymphocytes 3
endometrium 2
kidney 2
mammary gland 1
liver 1
Ezh2 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 68 53.08 Quite High
palliative 68 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Renal Cancer 3740 99.96 Very High Very High Very High
Cancer 3400 99.92 Very High Very High Very High
Breast Cancer 476 99.86 Very High Very High Very High
Metastasis 1224 99.84 Very High Very High Very High
Skin Cancer 204 98.36 Very High Very High Very High
Disease 340 97.72 Very High Very High Very High
Carcinoma 136 97.52 Very High Very High Very High
Endometrial Cancer 68 97.40 Very High Very High Very High
Apoptosis 136 96.92 Very High Very High Very High
Death 476 96.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For immunohistochemical assessment of EZH2 expression, frequency of nuclear staining was evaluated using a semiquantitative score: 0 = no expression; 1 = positivity in 1 to 5% = low expression; 2 = positivity in >5 to 25% = intermediate expression; 3 = positivity in >25 to 50% = high expression; and 4 = positivity in more than 50% = very high expression.
Gene_expression (expression) of EZH2
1) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.27 Pain Relevance 0
Altogether, 520 cases (non-metastatic disease n = 433, metastatic disease n = 87) were scored for expression of EZH2.
Gene_expression (expression) of EZH2 associated with metastasis
2) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.56 Pain Relevance 0
Vice versa, inhibition of EZH2 expression by antisense constructs or RNA interference (RNAi) resulted in growth inhibition of cancer cells [9,10], and induced anoikis in circulating prostate carcinoma precursor cells [11] or apoptotic cell death in breast cancer cells [12].
Gene_expression (expression) of EZH2 in apoptotic cell associated with cancer, breast cancer, prostate cancer, apoptosis and death
3) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.30 Pain Relevance 0
Multivariate Cox regression analyses on RCC outcome included tumor stage, Fuhrman's grading, Karnofsky performance status, age, sex, histopathological subtype, and EZH2 expression.
Gene_expression (expression) of EZH2 associated with cancer and renal cancer
4) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.22 Pain Relevance 0
In line, EZH2 expression could be detected in the proliferating parabasal cell layer in normal cervical epithelium [14] and in proliferating cells of normal mammary gland tissue [38].
Gene_expression (expression) of EZH2 in mammary gland
5) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.03 Pain Relevance 0
This indicates that detectable EZH2 expression is not stringently restricted to tumor cells.
Gene_expression (expression) of EZH2 associated with cancer
6) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.06 Pain Relevance 0
We do not know whether this discrepancy is related to the different detection method for EZH2 expression.
Gene_expression (expression) of EZH2
7) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.24 Pain Relevance 0
Non-tumorous kidney tissue was mainly negative for EZH2 expression (Figure 1B), only sporadically proximal and distal tubular epithelial cells and infiltrating lymphocytes, if present in the tissue sample, stained positive for EZH2.
Gene_expression (expression) of EZH2 in lymphocytes
8) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.56 Pain Relevance 0
Expression of EZH2 was analyzed by immunohistochemistry using a mouse monoclonal anti-EZH2 antibody [15].
Spec (analyzed) Gene_expression (Expression) of EZH2
9) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.55 Pain Relevance 0
Mechanistically, EZH2 is likely to contribute to the growth of RCC cells, since silencing of EZH2 expression exerts profound anti-proliferative effects in RCC lines [13].
Gene_expression (expression) of EZH2 associated with renal cancer
10) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.03 Pain Relevance 0
For analyzing RCC patients without metastases, our Cox regression model-which included tumor stage, grading, Karnofsky performance index, age, sex, histopathological subtype, and EZH2 expression-revealed a concordance probability of 73.4% compared to 71.8% excluding EZH2 expression.
Gene_expression (expression) of EZH2 associated with cancer, renal cancer and metastasis
11) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.91 Pain Relevance 0.03
Furthermore, in both prostate [9,17] and breast cancer [7,17], EZH2 expression was associated to more aggressive tumor subgroups, indicating that EZH2 expression may also serve as a novel prognostic marker.
Gene_expression (expression) of EZH2 associated with cancer and breast cancer
12) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.41 Pain Relevance 0
In breast cancer, high EZH2 expression was a strong independent predictive parameter of outcome, providing a better information about CSS than other independent prognostic features [7].
Gene_expression (expression) of EZH2 associated with breast cancer
13) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.46 Pain Relevance 0
Apart form serving as a novel prognostic marker in RCC, EZH2 expression may also have therapeutic and diagnostic implications.
Gene_expression (expression) of EZH2 associated with renal cancer
14) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.02 Pain Relevance 0
In patients with metastatic disease, nuclear EZH2 expression above 5% and up to 50% was an independent predictor of poor CSS (Figure 2C).
Gene_expression (expression) of EZH2 associated with metastasis
15) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.11 Pain Relevance 0
Overexpression of EZH2 conferred cellular growth advantage in vitro [6,7], promoted invasion [7], and exhibited oncogenic properties in nude mice [8].
Gene_expression (Overexpression) of EZH2
16) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.15 Pain Relevance 0
Moreover, reactive infiltrating lymphocytes, which express detectable amounts of EZH2 protein [20], served as additional internal positive controls.
Gene_expression (express) of EZH2 in lymphocytes
17) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.19 Pain Relevance 0
For metastasized RCC, 1-5%, >5-25%, and >25-50% nuclear EZH2 expression was linked to decreased CSS when compared with tumors with undetectable EZH2 expression (HR 2.63, p = 0.043, HR 3.35, p = 0.013, HR 4.92, p = 0.003).
Gene_expression (expression) of EZH2 associated with cancer and renal cancer
18) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.96 Pain Relevance 0
For the group of very high (> 50%) EZH2 expression no significant influence on survival could be shown in comparison to the group with non-expression of EZH2.
Gene_expression (non) of EZH2
19) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 0.91 Pain Relevance 0
EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses, but revealed independent multivariate prognostic importance only in carcinoma of the endometrium and prostate [17].
Gene_expression (expression) of EZH2 in endometrium associated with carcinoma, endometrial cancer and skin cancer
20) Confidence 0.78 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.24 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox